IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products; LPD; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. The company also offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers and SARS-CoV-2 RT-PCR that are used in the human point-of-care medical diagnostics market; in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers; SNAP rapid assays test kits. In addition, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; veterinary software and services for independent veterinary clinics and corporate groups. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.

IDEXX Laboratories, Inc.

Initial Statement of Beneficial Ownership

Insider	Title	Transaction Type	Shares Traded	% of Shares Traded	% Chg. in Shares	End of Filing Shares	Price	Transaction Value	Filing Date	Transaction Date
Karen A. Peacock	Director Show All	Other Derivative Acquisition (Other Derivative Acquisition)	101.0	—	—	101.0	—	—	03 Dec 2025	01 Dec 2025 - 01 Dec 2025
Karen A. Peacock	Director Show All	Other Derivative Acquisition (Other Derivative Acquisition)	231.0	—	—	231.0	728.0 - 728.0	—	03 Dec 2025	01 Dec 2025 - 01 Dec 2025
Nimrata Khatra Hunt	Executive Vice President of Global Strategy & Commercial Show All	Derivative Exercise and Retained Stock (Derivative Exercise and Retained Stock)	3.1K	0.003888%	17.1%	21.3K	288.8 - 288.8	896.7K	10 Nov 2025	07 Nov 2025 - 07 Nov 2025
Nimrata Khatra Hunt	Executive Vice President of Global Strategy & Commercial Show All	Derivative Exercise and Sale (Derivative Exercise and Sale)	-9.4K	-0.011803%	—	21.3K	288.8 - 705.5	-2.7M	10 Nov 2025	07 Nov 2025 - 07 Nov 2025
Joseph L. Hooley	Independent Director Show All	Other Acquisition (Other Acquisition)	39.0	—	—	39.0	628.5 - 628.5	24.5K	03 Nov 2025	30 Oct 2025 - 30 Oct 2025
Karen A. Peacock
Jonathan J. Mazelsky
Martin Alderson Smith	—
Martin Alderson Smith	—
Joseph L. Hooley
Joseph L. Hooley
	—
M. Anne Szostak
M. Anne Szostak
Michael Erickson
Nimrata Khatra Hunt
Nimrata Khatra Hunt
Sharon E. Underberg
Sharon E. Underberg
Jonathan J. Mazelsky
Andrew Emerson
Andrew Emerson
Nimrata Khatra Hunt
Nimrata Khatra Hunt
Jonathan J. Mazelsky
Michael J. Lane
Jonathan J. Mazelsky
Michael J. Lane
Joseph L. Hooley
Michael P. Johnson